Background: Tolvaptan, a vasopressin V2 receptor antagonist, is the only approved disease-modifying therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD), yet real-world data on its long-term effectiveness remain limited. The gene discussed is AVPR2; the disease is autosomal dominant polycystic kidney disease.